Welcome to CDC stacks | Recommendation to temporarily suspend usage of GlaxoSmithKline Rotarix (Rotavirus) vaccine - 25220 | Health Alert Network (HAN)
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Recommendation to temporarily suspend usage of GlaxoSmithKline Rotarix (Rotavirus) vaccine
  • Published Date:
  • Source:
    HAN ; 311
  • Language:
Filetype[PDF-756.82 KB]

  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.) ; United States. Food and Drug Administration. ;
  • Series:
  • Description:
    Monday, March 22, 2010, 15:54 EDT (03:54 PM EDT)


    The U.S. Food and Drug Administration (FDA) has learned that DNA from porcine circovirus type 1 (PCV1), a virus not known to cause disease in humans, is present in the Rotarix vaccine. All available evidence indicates that there has been no increased risk to patients who have received this vaccine. PCVI is not known to cause any disease in animals or humans; therefore, it has not been routinely tested for in vaccine development. Rotarix has been extensively studied, before and after approval, and found to have an excellent safety record (i.e., no unusual adverse events). However, FDA is recommending that healthcare practitioners temporarily suspend usage of the Rotarix vaccine for rotavirus immunization in the United States while the agency learns more about the detection of components of the virus found in the vaccine.

  • Document Type:
  • Place as Subject:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: